

Publications for Samuel Banister

2019

Kevin, R., Anderson, L., McGregor, I., Boyd, R., Manning, J., Glass, M., Connor, M., Banister, S. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. *Frontiers in Pharmacology*, 10(595), 1-9. [More Information]

Banister, S., Arnold, J., Connor, M., Glass, M., McGregor, I. (2019). Dark classics in chemical neuroscience: delta9-tetrahydrocannabinol. *ACS Chemical Neuroscience*, 10(5), 2160-2175. [More Information]

Banister, S., Adams, A., Kevin, R., MacDonald, C., Glass, M., Boyd, R., Connor, M., McGregor, I., Havel, C., Bright, S., et al (2019). Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold-hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. *Drug Testing and Analysis*, 11(2), 279-291. [More Information]

Banister, S., Kevin, R., Martin, L., Adams, A., MacDonald, C., Manning, J., Boyd, R., Cunningham, M., Stevens, M., McGregor, I., et al (2019). The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. *Drug Testing and Analysis*, 11(7), 976-989. [More Information]

2018

Mogler, L., Franz, F., Rentsch, D., Angerer, V., Weinfurter, G., Longworth, M., Banister, S., Kassiou, M., Moosmann, B., Auwarter, V. (2018). Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples. *Drug Testing and Analysis*, 10(1), 196-205. [More Information]

Sun, W., Nguyen, K., Fitch, W., Banister, S., Tang, H., Zhang, X., Yu, L., Engleman, E., Rajadas, J. (2018). In vitro and in vivo metabolite identification of a novel benzimidazole compound ZLN005 by liquid chromatography/tandem mass spectrometry. *Rapid Communications in Mass Spectrometry*, 32(6), 480-488. [More Information]

Brandehoff, N., Adams, A., McDaniel, K., Banister, S., Gerona, R., Monte, A. (2018). Synthetic cannabinoid "Black Mamba" infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN Cohort. *Clinical Toxicology*, 56(3), 193-198. [More Information]

Banister, S., Connor, M. (2018). The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. In Hans H. Maurer, Simon D. Brandt (Eds.), *New Psychoactive Substances*, (pp. 1-36). Cham: Springer. [More Information]

Banister, S., Connor, M. (2018). The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In Hans H. Maurer, Simon D. Brandt (Eds.), *New Psychoactive Substances*, (pp. 165-190). Cham: Springer. [More Information]

Banister, S., Olson, A., Winchester, M., Stuart, J., Edington, A., Kevin, R., Longworth, M., Herrera, M., Connor, M., McGregor, I., Kassiou, M., et al (2018). The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. *Drug Testing and Analysis*, 10(7), 1099-1109. [More Information]

2017

Adams, A., Banister, S., Irizarry, L., Trecki, J., Schwartz, M., Gerona, R. (2017). "zombie" outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. *New England Journal of Medicine*, 376(3), 235-242. [More Information]

Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. *Journal of Psychopharmacology*, 31(6), 757-769. [More Information]

Sridharan, S., Lepelletier, F., Trigg, W., Banister, S., Reekie, T., Kassiou, M., Gerhard, A., Hinz, R., Boutin, H. (2017). Comparative evaluation of three TSPO PET radiotracers in a LPS-induced model of mild neuroinflammation in rats. *Molecular Imaging and Biology*, 19(1), 77-89. [More Information]

Werry, E., King, V., Barron, M., Banister, S., Sokias, R., Kassiou, M. (2017). Derivatives of the pyrazolo[1,5-a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma. *European Journal of Pharmaceutical Sciences*, 96, 186-192. [More Information]

Longworth, M., Banister, S., Boyd, R., Kevin, R., Connor, M., McGregor, I., Kassiou, M. (2017). Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. *ACS Chemical Neuroscience*, 8(10), 2159-2167. [More Information]

Longworth, M., Connor, M., Banister, S., Kassiou, M. (2017). Synthesis and pharmacological profiling of the metabolites of synthetic cannabinoid drugs APICA, STS-135, ABD-PINACA, and 5F-ADB-PINACA. *ACS Chemical Neuroscience*, 8(8),

1673-1680. [More Information]

2016

Conroy, T., Manohar, M., Gong, Y., Wilkinson, S., Webster, M., Lieberman, B., Banister, S., Reekie, T., Mach, R., Rendina, L., Kassiou, M. (2016). A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines. *Organic and Biomolecular Chemistry*, 14(39), 9388-9405. [More Information]

Palner, M., Beinat, C., Banister, S., Zanderigo, F., Park, J., Shen, B., Hjoernevik, T., Jung, J., Lee, B., Kim, S., et al (2016). Effects of common anesthetic agents on [18F]flumazenil binding to the GABAA receptor. *EJNMMI Research*, 6(1), 1-11. [More Information]

Springer, Y., Gerona, R., Scheunemann, E., Shafer, S., Lin, T., Banister, S., Cooper, M., Castrodale, L., Levy, M., Butler, J., et al (2016). Increase in adverse reactions associated with use of synthetic cannabinoids - Anchorage, Alaska, 2015-2016. *Morbidity and Mortality Weekly Report*, 65(40), 1108-1111. [More Information]

Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. *ACS Chemical Neuroscience*, 7(9), 1241-1254. [More Information]

Longworth, M., Banister, S., Mack, J., Glass, M., Connor, M., Kassiou, M. (2016). The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. *Forensic Toxicology*, 34(2), 286-303. [More Information]

Beinat, C., Banister, S., Herrera, M., Kassiou, M. (2016). The recent development of $\alpha 7$ nicotinic acetylcholine receptor (nAChR) ligands as therapeutic candidates for the treatment of central nervous system (CNS) diseases. *Current Pharmaceutical Design*, 22(14), 2134-2151. [More Information]

2015

Wilkinson, S., Banister, S., Kassiou, M. (2015). Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. *Australian Journal of Chemistry*, 68(1), 4-8. [More Information]

Banister, S., Stuart, J., Kevin, R., Edington, A., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. *ACS Chemical Neuroscience*, 6(8), 1445-1458. [More Information]

Banister, S., Beinat, C., Wilkinson, S., Shen, B., Bartoli, C., Selleri, S., Da Pozzo, E., Martini, C., Chin, F., Kassiou, M.

(2015). Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). *European Journal of Medicinal Chemistry*, 93, 392-400. [More Information]

Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. *ACS Chemical Neuroscience*, 6(9), 1546-1559. [More Information]

Manohar, M., Banister, S., Beinat, C., O'Brien-Brown, J., Kassiou, M. (2015). Recent advances in the development of sigma-1 receptor ligands. *Australian Journal of Chemistry*, 68, 600-609. [More Information]

Beinat, C., Reekie, T., Banister, S., O'Brien-Brown, J., Xie, T., Olson, T., Xiao, Y., Harvey, A., O'Connor, S., Coles, C., Kassiou, M., et al (2015). Structure-activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at $\alpha 7$ nAChRs through incorporation of known structural motifs. *European Journal of Medicinal Chemistry*, 95, 277-301. [More Information]

Banister, S., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., Wilkinson, S., Kevin, R., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. *Forensic Toxicology*, 33(2), 355-366. [More Information]

Beinat, C., Banister, S., Herrera, M., Law, V., Kassiou, M. (2015). The therapeutic potential of $\alpha 7$ nicotinic acetylcholine receptor ($\alpha 7$ nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. *CNS Drugs*, 29(7), 529-542. [More Information]

2014

Liang, V., Ullrich, M., Lam, H., Chew, Y., Banister, S., Song, X., Zaw, T., Kassiou, M., Goetz, J., Nicholas, H. (2014). Altered proteostasis in aging and heat shock response in *C. elegans* revealed by analysis of the global and de novo synthesized proteome. *Cellular and Molecular Life Sciences*, 71(17), 3339-3361. [More Information]

Ullrich, M., Liang, V., Chew, Y., Banister, S., Song, X., Zaw, T., Lam, H., Berber, S., Kassiou, M., Nicholas, H., Goetz, J. (2014). Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in *Caenorhabditis elegans*. *Nature Protocols*, 9(9), 2237-2255. [More Information]

Ribeiro, M., Vercouillie, J., Debais, S., Cottier, J., Bonnaud, I., Camus, V., Banister, S., Kassiou, M., Arlicot, N., Guilloteau, D. (2014). Could 18F DPA 714 PET imaging be interesting to use in the early post-stroke period? *European Journal of Nuclear Medicine and Molecular Imaging*, 4(28), 1-8. [More Information]

Zavitsanou, K., Lim, C., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S., Guillemain, G., Weickert, C. (2014). Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX2 inhibition. *Brain, Behavior, and Immunity*, 41, 173-181. [More Information]

Beinat, C., Banister, S., Hoban, J., Tsanaktisidis, J., Metaxas, A., Windhorst, A., Kassiou, M. (2014). Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. *Bioorganic & Medicinal Chemistry Letters*, 24(3), 828-830. [More Information]

2013

Boutin, H., Prenant, C., Maroy, R., Galea, J., Greenhalgh, A., Smigova, A., Cawthorne, C., Julyan, P., Wilkinson, S., Banister, S., Kassiou, M., et al (2013). [(18)F]DPA-714: Direct comparison with [(11)C]PK11195 in a model of cerebral ischemia in rats. *PloS One*, 8673 (2), 1-9. [More Information]

Beinat, C., Banister, S., McErlean, C., Kassiou, M. (2013). A practical synthesis of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane. *Tetrahedron Letters*, 54(39), 5345-5347. [More Information]

Banister, S., Manoli, M., Barron, M., Werry, E., Kassiou, M. (2013). N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as sigma receptor ligands with potential neuroprotective effects. *Bioorganic and Medicinal Chemistry*, 21(19), 6038-6052. [More Information]

Banister, S., Manoli, M., Kassiou, M. (2013). The development of radiotracers for imaging sigma receptors in the central nervous system (CNS) using positron emission tomography (PET). *Journal of Labelled Compounds and Radiopharmaceuticals*, 56(3-4), 215-224. [More Information]

Banister, S., Wilkinson, S., Longworth, M., Stuart, J., Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2013). The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. *ACS Chemical Neuroscience*, 4(7), 1081-1092. [More Information]

2012

Banister, S., Rendina, L., Kassiou, M. (2012). 7-azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (sigma-2) receptor ligands. *Bioorganic and Medicinal Chemistry Letters*, 22(12), 4059-4063. [More Information]

Banister, S., Wilkinson, S., Hanani, R., Reynolds, A., Hibbs, D., Kassiou, M. (2012). A practical, multigram synthesis of the 2-(2-(4-alkoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA) class of high affinity translocator protein (TSPO) ligands. *Tetrahedron Letters*, 53(29), 3780-3783. [More

Information]

Banister, S., Manoli, M., Doddareddy, M., Hibbs, D., Kassiou, M. (2012). A σ_1 receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDS). *Bioorganic & Medicinal Chemistry Letters*, 22(19), 6053-6058. [More Information]

Beinat, C., Banister, S., Prehn, S., Doddareddy, M., Hibbs, D., Sako, M., Chebib, M., Tran, T., Al-Muhtasib, N., Xiao, Y., Kassiou, M. (2012). Consequences of linker length alteration of the α_7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333. *Bioorganic and Medicinal Chemistry Letters*, 22(7), 2380-2384. [More Information]

Moussa, I., Banister, S., Manoli, M., Doddareddy, M., Cui, J., Mach, R., Kassiou, M. (2012). Exploration of ring size in a series of cyclic vicinal diamines with sigma(1) receptor-affinity. *Bioorganic & Medicinal Chemistry Letters*, 22(17), 5493-5497. [More Information]

Banister, S., Wilkinson, S., Connor, M., McGregor, I., Kassiou, M. (2012). Medicinal chemists breaking bad: The clandestine rational design of cannabimimetic indoles as drugs of abuse. *The clandestine rational design of cannabimimetic indoles as drugs of abuse*. *Frontiers in medicinal chemistry*, Australia: RACI.

Banister, S., Kassiou, M. (2012). The Therapeutic Potential of Sigma (sigma) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence. *Current Pharmaceutical Design*, 18(7), 884-901. [More Information]

2011

Dolle, F., Le Helleix, S., Schollhorn-Peyronneau, M., Saba, W., Banister, S., Tournier, N., Valette, H., Kassiou, M. (2011). Carbon-11-labelling of a novel, trishomocubane-derived, high affinity and selectivity DAT ligand. *Journal of Labelled Compounds and Radiopharmaceuticals*, 54(1), S276-S276.

Moussa, I., Banister, S., Akladios, F., Chua, S., Kassiou, M. (2011). Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine sigma(1) receptor ligands. *Bioorganic and Medicinal Chemistry Letters*, 21(19), 5707-5710. [More Information]

Banister, S., Moussa, I., Jorgensen, W., Chua, S., Kassiou, M. (2011). Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. *Bioorganic and Medicinal Chemistry Letters*, 21(12), 3622-3626. [More Information]

Banister, S., Yoo, D., Chua, S., Cui, J., Mach, R., Kassiou, M. (2011). N-aryllalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (sigma) receptor ligands. *Bioorganic and Medicinal Chemistry Letters*, 21(18), 5289-5292. [More Information]

Banister, S., Kassiou, M. (2011). Polycarbocyclic Scaffolds for the Development of Sigma (a) Receptor Ligands. *Royal*

Australian Chemical Institute Biomolecular Division Conference (4-8 December, 2011), Australia: RACI.

Moussa, I., Banister, S., Giboureau, N., Meikle, S., Kassiou, M. (2011). Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel β 1 receptor PET imaging agent. *Bioorganic and Medicinal Chemistry Letters*, 21(22), 6820-6823. [More Information]

Banister, S., Moussa, I., Beinat, C., Reynolds, A., Schiavini, P., Jorgensen, W., Kassiou, M. (2011). Trishomocubane as a Scaffold for the Development of Selective Dopamine Transporter (DAT) Ligands. *Bioorganic and Medicinal Chemistry Letters*, 21(1), 38-41. [More Information]

2010

Banister, S., Clegg, J., Hanani, R., Kassiou, M. (2010). 11-[[2-(3-fluorophenyl)ethyl](methyl)-amino]pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]-undecan-8-one. *Acta Crystallographica. Section E: Structure Reports Online*, 66(10), o2693-o2693. [More Information]

Moussa, I., Banister, S., Beinat, C., Giboureau, N., Reynolds, A., Kassiou, M. (2010). Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands. *Journal of Medicinal Chemistry*, 53(16), 6228-6239. [More Information]

Banister, S., Roeda, D., Dolle, F., Kassiou, M. (2010). Fluorine-18 chemistry for PET: A concise introduction. *Current Radiopharmaceuticals*, 3(2), 68-80. [More Information]

Beinat, C., Banister, S., Moussa, I., Reynolds, A., McErlean, C., Kassiou, M. (2010). Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists. *Current Medicinal Chemistry*, 17(34), 4166-4190. [More Information]

Banister, S., Moussa, I., Jordan, M., Coster, M., Kassiou, M. (2010). Oxo-bridged isomers of aza-trishomocubane sigma (o) receptor ligands: $\frac{1}{2}$ Synthesis, in vitro binding, and molecular modeling. *Bioorganic and Medicinal Chemistry Letters*, 20(1), 145-148. [More Information]

2009

Banister, S., Coster, M., Kassiou, M. (2009). A versatile polycyclic scaffold for the discovery of selective sigma (sigma) receptor ligands. *7th AFMC International Medicinal Chemistry Symposium*, Cairns.

2008

Banister, S., Coster, M., Kassiou, M. (2008). Structure-Activity Relationships of Polycyclic Sigma Receptor Ligands. *17th International Conference on Organic Synthesis*, Australia: IUPAC.

Banister, S., Coster, M., Kassiou, M. (2008). Structure-Activity Relationships of Polycyclic Sigma Receptor Ligands. *Drug*

Design for Diseases of the Brain Symposium (2008), Australia: Drug Design for Diseases of the Brain Symposium.

Banister, S., Coster, M., Kassiou, M. (2008). Trishomocubanes as Selective Sigma (o) Receptor Ligands. *Royal Australian Chemical Institute 3D at the Cove - Drug Discovery & Development*, Australia: Royal Australian Chemical Institute.

Banister, S., Coster, M., Kassiou, M. (2008). Trishomocubanes as Selective Sigma (a) Receptor Ligands. *23rd Royal Australian Chemical Institute Organic Chemistry Conference*, Australia: RACI.

2007

Banister, S., Clegg, J., Coster, M., Jolliffe, K., Kassiou, M. (2007). (1R,2S,3R,6S,7R,8S)-Tricyclo[6.2.1.0_{2,7}]-undeca-4,9-diene-3,6-diol. *Acta Crystallographica. Section E: Structure Reports Online*, E63, o92-o93. [More Information]

Banister, S., Coster, M., Kassiou, M. (2007). Rattling the Cage: Structure-Activity Relationships of Polycyclic Sigma Receptor Ligands. *21st International Congress for Heterocyclic Chemistry*, Australia: Heterocyclic Chemistry.

Liu, X., Banister, S., Christie, M., Banati, R., Meikle, S., Coster, M., Kassiou, M. (2007). Trishomocubanes: Novel sigma ligands modulate cocaine-induced behavioural effects. *European Journal of Pharmacology*, 555(1), 37-42. [More Information]

2006

Banister, S., Coster, M., Kassiou, M. (2006). Rattling the Cage: Structure-Activity Relationships of Polycyclic Sigma Receptor Ligands. *Royal Australian Chemical Institute Drug Design Amongst the Vines (2006)*, Australia: RACI.